-
1
-
-
0018117957
-
Treatment of severe aplastic anemia with antilymphocyte globulin and androgens
-
Gluckman E., Devergie A., Faille A., et al. Treatment of severe aplastic anemia with antilymphocyte globulin and androgens. Exp Hematol 1978, 6:679-687.
-
(1978)
Exp Hematol
, vol.6
, pp. 679-687
-
-
Gluckman, E.1
Devergie, A.2
Faille, A.3
-
2
-
-
0033973769
-
Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?
-
Barrett J., Saunthararajah Y., Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology?. Semin Hematol 2000, 37:15-29.
-
(2000)
Semin Hematol
, vol.37
, pp. 15-29
-
-
Barrett, J.1
Saunthararajah, Y.2
Molldrem, J.3
-
3
-
-
41849113445
-
Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance
-
Barrett A.J., Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Curr Hematol Malig Rep 2008, 3:23-28.
-
(2008)
Curr Hematol Malig Rep
, vol.3
, pp. 23-28
-
-
Barrett, A.J.1
Sloand, E.2
-
4
-
-
79951980136
-
Targeting immune dysregulation in myelodysplastic syndromes
-
Olnes M.J., Sloand E.M. Targeting immune dysregulation in myelodysplastic syndromes. JAMA 2011, 305:814-819.
-
(2011)
JAMA
, vol.305
, pp. 814-819
-
-
Olnes, M.J.1
Sloand, E.M.2
-
5
-
-
34347218247
-
Autoimmunity and malignancy in hematology-more than an association
-
Stern M., Buser A.S., Lohri A., Tichelli A., Nissen-Druey C. Autoimmunity and malignancy in hematology-more than an association. Crit Rev Oncol Hematol 2007, 63:100-110.
-
(2007)
Crit Rev Oncol Hematol
, vol.63
, pp. 100-110
-
-
Stern, M.1
Buser, A.S.2
Lohri, A.3
Tichelli, A.4
Nissen-Druey, C.5
-
7
-
-
0035136385
-
Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features
-
Saunthararajah Y., Molldrem J.L., Rivera M., et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol 2001, 112:195-200.
-
(2001)
Br J Haematol
, vol.112
, pp. 195-200
-
-
Saunthararajah, Y.1
Molldrem, J.L.2
Rivera, M.3
-
8
-
-
79955444925
-
Immune alterations in untreated and treated myelodysplastic syndrome
-
Mewawalla P., Dasanu C.A. Immune alterations in untreated and treated myelodysplastic syndrome. Expert Opin Drug Saf 2011, 10:351-361.
-
(2011)
Expert Opin Drug Saf
, vol.10
, pp. 351-361
-
-
Mewawalla, P.1
Dasanu, C.A.2
-
9
-
-
61849168098
-
IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome
-
Kordasti S.Y., Afzali B., Lim Z., et al. IL-17-producing CD4(+) T cells, pro-inflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009, 145:64-72.
-
(2009)
Br J Haematol
, vol.145
, pp. 64-72
-
-
Kordasti, S.Y.1
Afzali, B.2
Lim, Z.3
-
11
-
-
0036400123
-
Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome
-
Melenhorst J.J., Eniafe R., Follmann D., Nakamura R., Kirby M., Barrett A.J. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002, 119:97-105.
-
(2002)
Br J Haematol
, vol.119
, pp. 97-105
-
-
Melenhorst, J.J.1
Eniafe, R.2
Follmann, D.3
Nakamura, R.4
Kirby, M.5
Barrett, A.J.6
-
12
-
-
76749142133
-
Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome
-
Campregher P.V., Srivastava S.K., Deeg H.J., Robins H.S., Warren E.H. Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. Exp Hematol 2010, 38:202-212.
-
(2010)
Exp Hematol
, vol.38
, pp. 202-212
-
-
Campregher, P.V.1
Srivastava, S.K.2
Deeg, H.J.3
Robins, H.S.4
Warren, E.H.5
-
13
-
-
67650065350
-
Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset
-
Fozza C., Contini S., Galleu A., et al. Patients with myelodysplastic syndromes display several T-cell expansions, which are mostly polyclonal in the CD4(+) subset and oligoclonal in the CD8(+) subset. Exp Hematol 2009, 37:947-955.
-
(2009)
Exp Hematol
, vol.37
, pp. 947-955
-
-
Fozza, C.1
Contini, S.2
Galleu, A.3
-
14
-
-
34547957665
-
CD4+CD25 high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS)
-
Kordasti S.Y., Ingram W., Hayden J., et al. CD4+CD25 high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007, 110:847-850.
-
(2007)
Blood
, vol.110
, pp. 847-850
-
-
Kordasti, S.Y.1
Ingram, W.2
Hayden, J.3
-
15
-
-
84859584423
-
Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?
-
Fozza C., Longinotti M. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?. Eur J Haematol 2012, 88:380-387.
-
(2012)
Eur J Haematol
, vol.88
, pp. 380-387
-
-
Fozza, C.1
Longinotti, M.2
-
16
-
-
7344223859
-
Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles
-
Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 1998, 102:1314-1322.
-
(1998)
Br J Haematol
, vol.102
, pp. 1314-1322
-
-
Molldrem, J.J.1
Jiang, Y.Z.2
Stetler-Stevenson, M.3
Mavroudis, D.4
Hensel, N.5
Barrett, A.J.6
-
17
-
-
0037111548
-
Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
-
Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002, 100:3639-3645.
-
(2002)
Blood
, vol.100
, pp. 3639-3645
-
-
Kochenderfer, J.N.1
Kobayashi, S.2
Wieder, E.D.3
Su, C.4
Molldrem, J.J.5
-
18
-
-
23044473715
-
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
-
Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
-
(2005)
Blood
, vol.106
, pp. 841-851
-
-
Sloand, E.M.1
Mainwaring, L.2
Fuhrer, M.3
-
19
-
-
79953100658
-
T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy
-
Sloand E.M., Melenhorst J.J., Tucker Z.C., et al. T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapy. Blood 2011, 117:2691-2699.
-
(2011)
Blood
, vol.117
, pp. 2691-2699
-
-
Sloand, E.M.1
Melenhorst, J.J.2
Tucker, Z.C.3
-
20
-
-
0031888417
-
Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
-
Jonasova A., Neuwirtova R., Cermak J., et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 1998, 200:304-309.
-
(1998)
Br J Haematol
, vol.200
, pp. 304-309
-
-
Jonasova, A.1
Neuwirtova, R.2
Cermak, J.3
-
21
-
-
77952602288
-
Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study
-
Scott B.L., Ramakrishnan A., Fosdal M., et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Scott Br J Haematol 2010, 149:706-710.
-
(2010)
Scott Br J Haematol
, vol.149
, pp. 706-710
-
-
Scott, B.L.1
Ramakrishnan, A.2
Fosdal, M.3
-
22
-
-
0030695069
-
Antithymocyte globulin for patients with myelodysplastic syndrome
-
Molldrem J.J., Caples M., Mavroudis D., Plante M., Young N.S., Barrett A.J. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 1997, 99:699-705.
-
(1997)
Br J Haematol
, vol.99
, pp. 699-705
-
-
Molldrem, J.J.1
Caples, M.2
Mavroudis, D.3
Plante, M.4
Young, N.S.5
Barrett, A.J.6
-
23
-
-
23044473715
-
Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome
-
Sloand E.M., Mainwaring L., Fuhrer M., et al. Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. Blood 2005, 106:841-851.
-
(2005)
Blood
, vol.106
, pp. 841-851
-
-
Sloand, E.M.1
Mainwaring, L.2
Fuhrer, M.3
-
24
-
-
45149093744
-
Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy
-
Sloand E.M., Wu C.O., Greenberg P., Young N., Barrett J. Factors affecting response and survival in patients with myelodysplasia treated with immunosuppressive therapy. J Clin Oncol 2008, 26:2505-2511.
-
(2008)
J Clin Oncol
, vol.26
, pp. 2505-2511
-
-
Sloand, E.M.1
Wu, C.O.2
Greenberg, P.3
Young, N.4
Barrett, J.5
-
25
-
-
0036720903
-
HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome
-
Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 2002, 100:1570-1574.
-
(2002)
Blood
, vol.100
, pp. 1570-1574
-
-
Saunthararajah, Y.1
Nakamura, R.2
Nam, J.M.3
-
26
-
-
0141923848
-
A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome
-
Saunthararajah Y., Nakamura R., Wesley R., Wang Q.J., Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003, 102:3025-3027.
-
(2003)
Blood
, vol.102
, pp. 3025-3027
-
-
Saunthararajah, Y.1
Nakamura, R.2
Wesley, R.3
Wang, Q.J.4
Barrett, A.J.5
-
27
-
-
33846692197
-
Treatment of myelodysplastic syndrome with cyclosporin A
-
Chen S., Jiang B., Da W., Gong M., Guan M. Treatment of myelodysplastic syndrome with cyclosporin A. Int J Hematol 2007, 85:11-17.
-
(2007)
Int J Hematol
, vol.85
, pp. 11-17
-
-
Chen, S.1
Jiang, B.2
Da, W.3
Gong, M.4
Guan, M.5
-
28
-
-
34548737638
-
A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response
-
Ishikawa T., Tohyama K., Nakao S., et al. A prospective study of cyclosporine A treatment of patients with low-risk myelodysplastic syndrome: presence of CD55(-)CD59(-) blood cells predicts platelet response. Int J Hematol 2007, 86:150-157.
-
(2007)
Int J Hematol
, vol.86
, pp. 150-157
-
-
Ishikawa, T.1
Tohyama, K.2
Nakao, S.3
-
29
-
-
0034084440
-
Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies
-
Catalano L., Selleri C., Califano C., et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica 2000, 85:133-138.
-
(2000)
Haematologica
, vol.85
, pp. 133-138
-
-
Catalano, L.1
Selleri, C.2
Califano, C.3
-
30
-
-
0033965450
-
Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele
-
Okamoto T., Okada M., Yamada S., et al. Good response to cyclosporine therapy in patients with myelodysplastic syndromes having the HLA-DRB1*1501 allele. Leukemia 2000, 14:344-346.
-
(2000)
Leukemia
, vol.14
, pp. 344-346
-
-
Okamoto, T.1
Okada, M.2
Yamada, S.3
-
31
-
-
0036366738
-
Treatment of myelodysplasia with oral cyclosporin
-
Atoyebi W., Bywater L., Rawlings L., Brunskill S., Littlewood T.J. Treatment of myelodysplasia with oral cyclosporin. Clin Lab Haematol 2002, 24:211-214.
-
(2002)
Clin Lab Haematol
, vol.24
, pp. 211-214
-
-
Atoyebi, W.1
Bywater, L.2
Rawlings, L.3
Brunskill, S.4
Littlewood, T.J.5
-
32
-
-
0345701967
-
A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia
-
Killick S.B., Mufti G., Cavenagh J.D., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol 2003, 120:679-684.
-
(2003)
Br J Haematol
, vol.120
, pp. 679-684
-
-
Killick, S.B.1
Mufti, G.2
Cavenagh, J.D.3
-
33
-
-
0037443455
-
Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
-
Steensma D.P., Dispenzieri A., Moore S.B., Schroeder G., Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 2003, 101:2156-2158.
-
(2003)
Blood
, vol.101
, pp. 2156-2158
-
-
Steensma, D.P.1
Dispenzieri, A.2
Moore, S.B.3
Schroeder, G.4
Tefferi, A.5
-
34
-
-
1542608520
-
A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
-
Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 2004, 18:460-465.
-
(2004)
Leukemia
, vol.18
, pp. 460-465
-
-
Stadler, M.1
Germing, U.2
Kliche, K.O.3
-
35
-
-
79951996237
-
Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99
-
Passweg J.R., Giagounidis A.A., Simcock M., et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011, 29:303-309.
-
(2011)
J Clin Oncol
, vol.29
, pp. 303-309
-
-
Passweg, J.R.1
Giagounidis, A.A.2
Simcock, M.3
-
36
-
-
33744492061
-
Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
-
Broliden P.A., Dahl I.M., Hast R., et al. Antithymocyte globulin and cyclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 2006, 91:667-670.
-
(2006)
Haematologica
, vol.91
, pp. 667-670
-
-
Broliden, P.A.1
Dahl, I.M.2
Hast, R.3
-
37
-
-
78650354414
-
Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions
-
Sloand E.M., Olnes M.J., Shenoy A., et al. Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol 2010, 28:5166-5173.
-
(2010)
J Clin Oncol
, vol.28
, pp. 5166-5173
-
-
Sloand, E.M.1
Olnes, M.J.2
Shenoy, A.3
-
38
-
-
20144363954
-
Antileukemic activity of rapamycin in acute myeloid leukemia
-
Recher C., Beyne-Rauzy O., Demur C., et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005, 105:2527-2534.
-
(2005)
Blood
, vol.105
, pp. 2527-2534
-
-
Recher, C.1
Beyne-Rauzy, O.2
Demur, C.3
-
39
-
-
0036174289
-
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor
-
Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
-
(2002)
Nat Med
, vol.8
, pp. 128-135
-
-
Guba, M.1
von Breitenbuch, P.2
Steinbauer, M.3
-
40
-
-
20044396552
-
Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study
-
Platzbecker U., Haase M., Herbst R., et al. Activity of sirolimus in patients with myelodysplastic syndrome-results of a pilot study. Br J Haematol 2005, 128:625-630.
-
(2005)
Br J Haematol
, vol.128
, pp. 625-630
-
-
Platzbecker, U.1
Haase, M.2
Herbst, R.3
-
41
-
-
33745968917
-
Clinical applications and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
-
Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical applications and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
-
(2006)
Blood
, vol.108
, pp. 419-425
-
-
Cheson, B.D.1
Greenberg, P.L.2
Bennett, J.M.3
-
42
-
-
0031464758
-
Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes
-
Kitagawa M., Saito I., Kuwata T., et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997, 11:2049-2054.
-
(1997)
Leukemia
, vol.11
, pp. 2049-2054
-
-
Kitagawa, M.1
Saito, I.2
Kuwata, T.3
-
43
-
-
0031656518
-
A role for tumor necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome
-
Gersuk G.M., Beckham C., Loken M.R., et al. A role for tumor necrosis factor-a, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998, 103:176-188.
-
(1998)
Br J Haematol
, vol.103
, pp. 176-188
-
-
Gersuk, G.M.1
Beckham, C.2
Loken, M.R.3
-
44
-
-
0037411227
-
Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes
-
Sawanobori M., Yamaguchi S., Hasegawa M., et al. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003, 27:583-591.
-
(2003)
Leuk Res
, vol.27
, pp. 583-591
-
-
Sawanobori, M.1
Yamaguchi, S.2
Hasegawa, M.3
-
45
-
-
18044404398
-
Immunosuppressive therapy for patients with refractory anemia
-
Asano Y., Maeda M., Uchida N., et al. Immunosuppressive therapy for patients with refractory anemia. Ann Hematol 2001, 80:634-638.
-
(2001)
Ann Hematol
, vol.80
, pp. 634-638
-
-
Asano, Y.1
Maeda, M.2
Uchida, N.3
-
46
-
-
23944523111
-
Cyclosporin A in myelodysplastic syndrome: a preliminary report
-
Dixit A., Chatterjee T., Mishra P., et al. Cyclosporin A in myelodysplastic syndrome: a preliminary report. Ann Hematol 2005, 84:565-568.
-
(2005)
Ann Hematol
, vol.84
, pp. 565-568
-
-
Dixit, A.1
Chatterjee, T.2
Mishra, P.3
-
47
-
-
0036840455
-
Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies
-
Selleri C., Maciejewski J.P., Catalano L., et al. Effects of cyclosporine on hematopoietic and immune functions in patients with hypoplastic myelodysplasia: in vitro and in vivo studies. Cancer 2002, 95:1911-1922.
-
(2002)
Cancer
, vol.95
, pp. 1911-1922
-
-
Selleri, C.1
Maciejewski, J.P.2
Catalano, L.3
-
48
-
-
0242643661
-
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes
-
Yazji S., Giles F.J., Tsimberidou A.M., et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 2003, 17:2101-2106.
-
(2003)
Leukemia
, vol.17
, pp. 2101-2106
-
-
Yazji, S.1
Giles, F.J.2
Tsimberidou, A.M.3
|